Cancer immunotherapy
Alemany’s & Piulats’s lab

DESCRIPTION

Our main aim is to develop new anticancer treatments based on novel designs of oncolytic adenoviruses, combining them with mesenchymal stem cells and cellular therapies derived from tumor reactive T-lymphocytes against solid tumors.

The Cancer Immunotherapy group, led by Dr Piulats and Dr Alemany, is dedicated to develop new immunotherapies based on oncolytic adenoviruses or advanced therapy medicinal products (ATMPs) to treat the so-called “cold” tumors and rare malignancies. Oncolytic viruses represent a double antitumor strategy: they have an oncolytic activity and on top of that, they promote lymphocyte infiltration and immune responses against tumors. We are designing and evaluating new oncolytic adenovirus to improve their Intratumor diffusion and tumor reactivity and testing those using murine models. We are developing CAR-NK cells models, cell therapies based on autoreactive TCRs from patients and combined ATMP using virus and mesenchymal stem cells. We combine clinical and translational research, and we have led different clinical trials based on immunotherapy, demonstrating the feasibility of immunotherapy approaches to treat this kind of tumors.

Group members

Ramón Alemany Bonastre

Group leaders

Josep Maria Piulats Rodríguez

Group leaders

Publications

Evolving Status of Clinical Immunotherapy with Oncolytic Adenovirus

2 de February de 2021/in Alemany’s & Piulats’s lab/by

Clin Cancer Res. 2021 Jun 1;27(11):2979-2988. doi: 10.1158/1078-0432.CCR-20-1565. Epub 2021 Feb 1. ABSTRACT Cancer immunotherapy targeting immune checkpoint inhibitors shows efficacy in several human cancers, but “cold tumors” that lack immune cells are typically unresponsive. Among the potential therapeutic approaches that could “heat” or promote lymphocyte infiltration of cold tumors, oncolytic viruses have attracted interest […]

Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402)

8 de January de 2021/in Alemany’s & Piulats’s lab/by

J Clin Oncol. 2021 Feb 20;39(6):586-598. doi: 10.1200/JCO.20.00550. Epub 2021 Jan 8. ABSTRACT PURPOSE: This study aimed to assess the efficacy of the combination of nivolumab (nivo) plus ipilimumab (ipi) as a first-line therapy with respect to the 12-month overall survival (OS) in patients with metastatic uveal melanoma (MUM) who are not eligible for liver […]

FGFR Inhibition Overcomes Resistance to EGFR-targeted Therapy in Epithelial-like Cutaneous Carcinoma

2 de December de 2020/in Alemany’s & Piulats’s lab/by

Clin Cancer Res. 2021 Mar 1;27(5):1491-1504. doi: 10.1158/1078-0432.CCR-20-0232. Epub 2020 Dec 1. ABSTRACT PURPOSE: Recurrent and/or metastatic unresectable cutaneous squamous cell carcinomas (cSCCs) are treated with chemotherapy or radiotherapy, but have poor clinical responses. A limited response (up to 45% of cases) to EGFR-targeted therapies was observed in clinical trials with patients with advanced and […]

Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma

1 de December de 2020/in Alemany’s & Piulats’s lab/by

Clin Cancer Res. 2021 Feb 1;27(3):889-902. doi: 10.1158/1078-0432.CCR-20-2400. Epub 2020 Nov 30. ABSTRACT PURPOSE: Extracellular matrix (ECM) component hyaluronan (HA) facilitates malignant phenotypes of glioblastoma (GBM), however, whether HA impacts response to GBM immunotherapies is not known. Herein, we investigated whether degradation of HA enhances oncolytic virus immunotherapy for GBM. EXPERIMENTAL DESIGN: Presence of HA […]

Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment

6 de November de 2020/in Alemany’s & Piulats’s lab/by

Eur Urol. 2021 Jun;79(6):722-733. doi: 10.1016/j.eururo.2020.10.001. Epub 2020 Nov 3. ABSTRACT BACKGROUND: Taxanes are the most active chemotherapy agents in metastatic castration-resistant prostate cancer (mCRPC) patients; yet, resistance occurs almost invariably, representing an important clinical challenge. Taxane-platinum combinations have shown clinical benefit in a subset of patients, but the mechanistic basis and biomarkers remain elusive. […]

Research Projects

Name: Dr Ramón Alemany Bonastre
Role: Group leader (coPI)

Name: Dr Josep Maria Piulats Rodríguez, MD
Role: Group leader (coPI)

Name: Dr Rafael Moreno Olié
Role: Principal Investigator

Name: Dr María Dolores López Robles
Role: Postdoctoral researcher

Name: Dr Marcel Costa García
Role: Postdoctoral Researcher

Name: Dr Gabriel Espinosa Carrasco
Role: Postdoctoral researcher

Name: Sílvia Torres Manjón
Role: Lab manager

Name: Laura Moya Borrrego
Role: Predoctoral Researcher

Name: Pau Fiol Mata
Role: Predoctoral Researcher

Name: Luís Paul del Carpio Huerta, MD
Role: Predoctoral Researcher (Rio Ortega contract)

Name: Juan Antonio Marín Jiménez, MD
Role: Predoctoral Researcher (La Caixa- Inphinit Retaining)

Name: Sebastián Ciro Carné Martín
Role: Predoctoral Researcher

Name: Ainhoa Muñoz Metrino
Role: Technician

Name: Dr Carles Codony Servat
Role: Project manager

Collaborations

Dr Alemany has published 129 articles, several book chapters and 16 patents (5 in the exploitation phase) in the field of therapeutic use of adenoviruses as gene vectors or oncolytic viruses. Editor of the journals “Gene Therapy” “Cancer Gene Therapy” and “Human Gene Therapy”, President of the Spanish Society of Gene and Cellular Therapy from 2016 to 2018, and advisor to several biotech companies that develop oncolytic viruses (ORCA Therapeutics, Oncolytics Biotech, Sagetis). In 2009 he co-founded the company VCN Biosciences. GHe collaborates among othersc with: Cristina Fillat Fonts, IDIBAPS; Juan José Rojas Expósito, IDIBELL; Javier García Castro, ISCIII , Madrid; Manuel Ramírez Orellana, Hosp Niño Jesús, Madrid; Alena Gros Vidal, VHIO; Sonia Guedan Carrió, IDIBAPS.

Dr Piulats is chair for Uveal Melanoma in the Spanish Melanoma group. He is part of the IRCI (International Rare Cancer Initiative) and EURACAN for rare melanoma and rare cutaneous tumors. He collaborates with Dr Alvaro Aytes (Idibell) and Dr Himisha Beltran (Dana Farber) in prostate cancer (projects Fundación Mútua Madrileña and DoD Prostate Cancer) and with Dr Xavier Matías-Guiu and Dr Alena Gros in Gynecologic tumors (La MaratóTV3, Immune4all in Ayudas de Proyectos de Investigación de Medicina Personalizada de Precisión). He collaborates with Dr Moreno (ICO-Idibell) and Dr África González Murillo (Hospital Universitario del Niño Jesús) in the PULSE-UM clinical study and with Dr Juan Marín Liberal (ICO), Drs Alena Gros, Elena Garralda (VHIO), Dr Sergi Querol (Banc de sang i Teixits) and Dr Jesús García-Donas Jiménez (Centro Integral Oncológico Clara Campal) (Proyectos Clinica Independiente – ISCIII).

Presently Dr Piulats has begun a collaboration asking for new funding for novel treatments in metastatic uveal melanoma with Alena Gros (VHIO), Gal Cafri and Yochai Wolf from Sheba Research Institute in Israel and Udai Kammula from UPMC in USA.

Dr Moreno collaborates in the development of NK-CAR cells with Dr Ana Sureda (ICO). He also collaborates with Dr. Marta Alonso (CIMA-University of Navarra) in the development towards a protocol and clinical application for GBM.

Cancer immunotherapy Alemany’s & Piulats’s lab

DESCRIPTION

Ramón Alemany Bonastre

Group leaders

Josep Maria Piulats Rodríguez

Group leaders

Rafael Moreno Olié

Researchers

María Dolores López Robles

Researchers

Gabriel Espinosa Carrasco

Researchers

Marcel Costa García

Researchers

Luís Paul del Carpio Huerta

Researchers

Juan Antonio Marín Jiménez

Young investigators

Laura Moya Borrego

Young investigators

Pau Fiol Mata

Young investigators

Sebastián Ciro Carné Martín

Young investigators

Silvia Torres Manjón

Support staff

Ainhoa Muñoz Metrino

Support staff

Carles Codony Servat

Support staff

CONTACT US

Cancer immunotherapy
Alemany’s & Piulats’s lab